WFH Released New Evidence-Based Guidelines on AAV Gene Therapy for Hemophilia
World Federation of Hemophilia shared on LinkedIn:
”The WFH has released new evidence-based guidelines on AAV gene therapy for hemophilia, covering eligibility, center readiness, infusion safety, and long-term monitoring.
A major step forward for people with bleedingdisorders.
Find out more”
The World Federation of Hemophilia (WFH) has released a new evidence-based clinical practice guideline focused on adeno-associated virus (AAV) gene therapy for people with hemophilia (PwH).
This marks the addition of a dedicated gene therapy section within the broader WFH Guidelines for the Management of Hemophilia.
The guideline offers practical, up-to-date recommendations to support clinicians and patients in navigating this rapidly advancing treatment landscape.
It aims to promote safe, informed, and equitable use of gene therapy across the global bleeding disorders community.
Stay updated with Hemostasis Today.
-
Apr 11, 2026, 13:51David McIntosh: Vital Plasma Derived Medicines – The Anomalous UK Scene
-
Apr 11, 2026, 13:47Samrawit Terefe: O Negative Blood Is the Universal Donor With Extreme Scarcity
-
Apr 11, 2026, 13:39Dheeraj Garg: Rethinking Cardiovascular Disease – A Cardiologist’s Perspective
-
Apr 11, 2026, 13:37Kushal Bhatia: Is The 4.5-Hour Thrombolysis Window Officially Outdated?
-
Apr 11, 2026, 13:35William Aird: Why Did Mammalian Red Blood Cells Give Up Their Nucleus?
-
Apr 11, 2026, 13:30Ken Kuang: Gravity Is Constant, But Your Vein Health Doesn’t Have to Be
-
Apr 11, 2026, 13:21Mascha Kern: Measuring Gender’s Role in Stroke and Migraine
-
Apr 11, 2026, 13:10Danique Steeghs: Key Findings from a Microfluidic Chemiluminescent Thrombin Generation Assay
-
Apr 11, 2026, 13:06Shanvi Mahi: A Validated Tool to Explore Lived Experiences After Stroke Rehabilitation